Johnson & Johnson 과거 순이익 실적
과거 기준 점검 3/6
Johnson & Johnson은 연평균 6.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 9.7% 증가했습니다. 매출은 연평균 1.6%의 비율로 증가했습니다. Johnson & Johnson의 자기자본이익률은 25.9%이고 순이익률은 21.8%입니다.
핵심 정보
6.82%
순이익 성장률
9.54%
주당순이익(EPS) 성장률
| Pharmaceuticals 산업 성장률 | 5.95% |
| 매출 성장률 | 1.65% |
| 자기자본이익률 | 25.92% |
| 순이익률 | 21.83% |
| 최근 순이익 업데이트 | 29 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
Seeking Alpha • May 23
Johnson & Johnson: A Dividend King, But Priced Appropriately, Big Conference Slate
Summary Johnson & Johnson is rated Hold, trading near intrinsic value with limited upside based on a 20x multiple and $12 normalized EPS. Q1 results showed 10% sales growth and a $450M revenue beat, with management raising FY 2026 guidance and extending the dividend growth streak to 64 years. JNJ faces headwinds from biosimilar and generic competition, MedTech challenges, and commercial sluggishness, but maintains strong FCF yield and a robust product pipeline. Technicals are mixed but lean bullish, with $235 as near-term resistance and investors advised to monitor upcoming conference commentary and sector momentum. Read the full article on Seeking Alpha
내러티브 업데이트 • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.내러티브 업데이트 • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.내러티브 업데이트 • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.
새로운 내러티브 • Mar 30
Johnson & Johnson (JNJ): The $100 Billion Revenue Frontier and the MedTech Evolution
Johnson & Johnson (JNJ) is currently trading at $242.83 USD on the NYSE as of the afternoon session on March 30, 2026, reflecting a steady 1% gain for the day. After a transformative 2025 that saw the full integration of its "pure-play" healthcare strategy following the Kenvue spin-off, the company has entered 2026 with significant momentum.내러티브 업데이트 • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.
새로운 내러티브 • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.내러티브 업데이트 • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.내러티브 업데이트 • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.내러티브 업데이트 • Jan 27
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Balanced Risk Reward
Analysts have raised their Johnson & Johnson fair value estimate by about US$13 to roughly US$224. This reflects slightly higher modeled revenue growth, a marginally higher future P/E, and supportive Street research that includes multiple recent price target increases from major firms across the sector.
새로운 내러티브 • Jan 25
Broad MedTech And Complex Therapy Platforms Will Define A Stronger Future Trajectory
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company that develops and sells pharmaceuticals and medical devices across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Jan 09
JNJ: Ortho Separation And Talc Risks Will Shape Balanced Forward Risk Reward
Analysts have nudged their fair value estimate for Johnson & Johnson slightly higher to about US$211 per share, reflecting updated views on revenue growth, profitability, and future P/E assumptions informed by recent price target increases and supportive research commentary on the company's pipeline and planned ortho separation. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of optimism around the pipeline, margin profile, and planned ortho separation, alongside ongoing attention to litigation and product risk.내러티브 업데이트 • Dec 19
JNJ Future Portfolio Separation And Litigation Resolution Will Shape Balanced Risk Reward Outlook
Analysts have raised their average price target on Johnson & Johnson by about $7 to roughly $209, reflecting slightly faster expected revenue growth, a modestly higher future earnings multiple, and confidence that portfolio reshaping and pipeline execution can offset near term margin pressure. Analyst Commentary Street research on Johnson & Johnson has turned incrementally more constructive, with multiple firms lifting price targets in response to stronger fundamentals and portfolio actions that are viewed as supportive of a faster growth profile.내러티브 업데이트 • Dec 05
JNJ: Future Reorganization And Litigation Outcomes Will Shape Risk Reward Balance
The analyst price target for Johnson & Johnson has been nudged higher, with fair value rising from approximately $200.82 to $202.54 per share, as analysts highlight slightly stronger long term revenue growth, modestly higher profit margins, and a richer future P/E multiple supported by an improving innovation pipeline and portfolio reshaping efforts. Analyst Commentary Recent research updates reflect a broadly constructive stance on Johnson & Johnson, with a growing number of firms highlighting improving fundamentals, a stronger growth profile, and a more compelling risk reward setup following the latest results and guidance.내러티브 업데이트 • Nov 21
JNJ: Upcoming Business Reorganization and Legal Risks Will Influence Future Performance
Johnson & Johnson's analyst price target has increased slightly from $199.56 to $200.82, as analysts cite stronger-than-expected sector performance and a constructive long-term industry outlook, which support the adjustment. Analyst Commentary Recent analyst commentary on Johnson & Johnson highlights a variety of perspectives related to the company's valuation, strategic direction, and future growth potential.내러티브 업데이트 • Nov 05
JNJ: Upcoming Portfolio Shifts and Legal Uncertainties Will Shape Risk-Reward Balance
Johnson & Johnson's fair value estimate has increased by $1.52 to $199.56, as analysts point to improving core growth metrics, recent strong quarterly results, and expectations for higher margins following portfolio changes. Analyst Commentary Recent Street research reveals a mix of optimism and caution among analysts following Johnson & Johnson’s latest results, portfolio changes, and evolving sector dynamics.내러티브 업데이트 • Oct 22
Analyst Commentary Drives Higher Valuation Targets for Johnson & Johnson Amid Positive Company Developments
Analysts have raised their fair value price target for Johnson & Johnson from approximately $185.13 to $198.03. They cite robust quarterly results, upcoming product launches, and anticipated growth and margin improvements from the company's business transformation initiatives as key reasons for the adjustment.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Johnson & Johnson가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 29 Mar 26 | 96,362 | 21,040 | 24,003 | 14,967 |
| 28 Dec 25 | 94,193 | 26,804 | 23,130 | 14,665 |
| 28 Sep 25 | 92,149 | 25,119 | 22,742 | 15,711 |
| 29 Jun 25 | 90,627 | 22,661 | 22,211 | 16,991 |
| 30 Mar 25 | 89,331 | 21,810 | 21,906 | 16,915 |
| 29 Dec 24 | 88,821 | 14,066 | 21,952 | 17,232 |
| 29 Sep 24 | 87,696 | 14,767 | 21,290 | 16,414 |
| 30 Jun 24 | 86,576 | 16,382 | 21,050 | 14,909 |
| 31 Mar 24 | 85,648 | 17,072 | 20,640 | 15,172 |
| 31 Dec 23 | 85,159 | 13,326 | 20,166 | 15,085 |
| 01 Oct 23 | 83,703 | 12,421 | 19,648 | 14,315 |
| 02 Jul 23 | 82,348 | 12,422 | 19,323 | 14,353 |
| 02 Apr 23 | 77,458 | 10,730 | 17,993 | 14,128 |
| 01 Jan 23 | 79,990 | 16,370 | 19,078 | 14,135 |
| 02 Oct 22 | 84,855 | 17,879 | 21,037 | 15,145 |
| 03 Jul 22 | 88,197 | 17,236 | 22,197 | 15,082 |
| 03 Apr 22 | 94,880 | 19,830 | 24,430 | 14,998 |
| 02 Jan 22 | 78,740 | 17,801 | 19,506 | 14,277 |
| 03 Oct 21 | 91,446 | 17,880 | 23,364 | 14,026 |
| 04 Jul 21 | 89,190 | 17,767 | 22,852 | 13,444 |
| 04 Apr 21 | 84,214 | 15,115 | 21,817 | 12,757 |
| 03 Jan 21 | 82,584 | 14,714 | 21,731 | 12,159 |
| 27 Sep 20 | 80,856 | 16,986 | 21,681 | 11,359 |
| 28 Jun 20 | 80,503 | 15,185 | 21,625 | 11,118 |
| 29 Mar 20 | 82,729 | 17,166 | 22,185 | 11,077 |
| 29 Dec 19 | 82,059 | 15,119 | 21,885 | 11,355 |
| 29 Sep 19 | 81,706 | 14,151 | 21,957 | 11,347 |
| 30 Jun 19 | 81,325 | 16,332 | 22,191 | 11,256 |
| 31 Mar 19 | 81,593 | 14,679 | 22,437 | 11,229 |
| 30 Dec 18 | 81,581 | 15,297 | 22,540 | 10,775 |
| 30 Sep 18 | 81,382 | 1,542 | 22,454 | 11,194 |
| 01 Jul 18 | 80,684 | 1,372 | 22,300 | 11,271 |
| 01 Apr 18 | 78,693 | 1,245 | 21,758 | 10,928 |
| 31 Dec 17 | 76,450 | 1,300 | 21,520 | 10,594 |
| 01 Oct 17 | 74,361 | 15,827 | 20,600 | 9,591 |
| 02 Jul 17 | 72,531 | 16,335 | 20,012 | 9,184 |
| 02 Apr 17 | 72,174 | 16,505 | 20,020 | 9,152 |
| 01 Jan 17 | 71,890 | 16,540 | 19,793 | 9,143 |
| 02 Oct 16 | 71,595 | 15,941 | 20,527 | 9,319 |
| 03 Jul 16 | 70,877 | 15,027 | 20,836 | 9,295 |
| 03 Apr 16 | 70,182 | 15,546 | 21,044 | 9,160 |
| 03 Jan 16 | 70,074 | 15,409 | 21,203 | 9,046 |
| 27 Sep 15 | 70,517 | 14,715 | 21,134 | 8,817 |
| 28 Jun 15 | 71,882 | 16,106 | 21,521 | 8,686 |
양질의 수익: JNJ는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: JNJ의 현재 순 이익률 (21.8%)은 지난해 (24.3%)보다 낮습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: JNJ의 수익은 지난 5년 동안 연평균 6.8% 증가했습니다.
성장 가속화: JNJ은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.
수익 대 산업: JNJ은 지난 1년 동안 수익이 감소(-3.2%)하여 Pharmaceuticals 업계 평균(-5%)과 비교하기 어렵습니다.
자기자본이익률
높은 ROE: JNJ의 자본 수익률(25.9%)은 높음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/25 19:53 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/29 |
| 연간 수익 | 2025/12/28 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Johnson & Johnson는 53명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |